Clinical trial

#Clinical trial #GSK #Protas

GSK signs agreement to streamline clinical trials 

GSK has announced an agreement with Protas to streamline clinical trials of vaccines and therapeutics.  The three-year agreement sets out to build on an existing two-year relationship and will broaden the scope of work across numerous projects. This includes Phase II and III trials within GSK’s respiratory,… Read More

#News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (11 – 15 May) 

News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW.  This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis.  The top stories:   … Read More

#News

KRAS
#Cancer research #Clinical trial #KRAS #Protein

Targeting the undruggable protein: What is the potential for KRAS inhibitors? 

Diana Turner explores the latest KRAS breakthroughs and how our understanding of this illusive protein has developed in recent years.  In September 2025, the inaugural Stephenson Global Prize was awarded to Dr Frank McCormick, Professor at the UCSF Helen Diller Family Comprehensive Cancer Center, for “groundbreaking discoveries that have transformed the fight… Read More

#Cancer Research #Exclusive Content

Mother helps child to use a nebuliser
#Clinical trial #Cystic fibrosis #Enterprise Therapeutics

Cystic fibrosis treatment could improve lung function 

A new treatment for cystic fibrosis (CF) could improve lung function in patients, results suggest.  ETD001, developed by biopharmaceutical company Enterprise Therapeutics, was trialled in a Phase II study as an inhaled treatment in the 10% of people with CF with the highest unmet medical need, who do… Read More

#News

Scientist in laboratory
#AI #Clinical trial #Phesi

AI not solving clinical trial flaws, report says 

AI tools are scaling flaws in clinical trials instead of solving them, analysis shows.  Analytics and data company Phesi revealed the findings from a global analysis of more than 600,000 clinical trial protocols.   Results show fewer than one in three (29.3%) protocols are linked to publicly documented patient… Read More

#News

#Autoimmune disease #Clinical trial #FDA

FDA treatment approval brings ‘hope’ to gMG patients 

The US Food and Drug Administration (FDA) has approved the first treatments for all serotypes of patients living with generalised myasthenia gravis (gMG).  The FDA’s label expansion of Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) now means gMG adult patients can treat all serotypes, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative. … Read More

#News #Regulatory

#ASGCT #Cell and gene therapy #Clinical trial #Haematology

Therapy for X-CGD shows early promise, Ensoma reports 

An in vivo therapy being developed to treat X-linked chronic granulomatous disease (X-CGD) has shown positive early results.  EN-374, developed by cellular engineering company Ensoma, has demonstrated tolerability in the first participant being evaluated in the Phase I/II trial.  The therapy is a first-in-class in vivo haematopoietic stem cell… Read More

#News

#Breast cancer #Clinical trial #Oncology #Ovarian cancer #Pancreatic cancer #Prostate cancer

Overcoming drug resistance with General Oncology

DDW Editor Reece Armstrong speaks to Jeff Glazier, CEO of General Oncology, about the challenges facing pancreatic cancer drug development and the company's activities in the space. RA: Why has pancreatic cancer remained so difficult to treat? JG: Pancreatic cancer is typically diagnosed at an advanced stage, is biologically aggressive, and rapidly develops resistance to therapy. Tumours are highly heterogeneous, both between… Read More

#Exclusive Content

Neuroendocrine tumours
#Clinical trial #Tumour biology

Trial launched to evaluate neuroendocrine tumour vaccine 

A Phase II trial evaluating a treatment for metastatic neuroendocrine tumours (NETs) has been launched.  SurVaxM, a peptide vaccine, has been developed by biotechnology company MimiVax and will be evaluated in a study conducted at Rosewell Park, New York.  The trial will evaluate SurVaxM in combination with temozolomide… Read More

#Cancer Research #News

CT scans of the brain
#Alzheimer's #Clinical trial

First patient dosed in Alzheimer’s agitation treatment 

The first patient has been dosed with a treatment for agitation in patients with Alzheimer’s disease (AD) dementia.  The Phase II/III SERENADA trial is evaluating the efficacy and safety of Deraphan, developed by biopharmaceutical company Exciva.  Deraphan is a combination of two clinically validated products: dextromethorphan, an NMDA… Read More

#News

FDA headquarters
#Clinical trial #FDA #Newron Pharmaceuticals #Schizophrenia

FDA pauses schizophrenia trial after patient death 

The US Food and Drug Administration (FDA) has paused a trial evaluating a drug for treatment-resistant schizophrenia (TRS) after the death of a participant.  Evenamide, developed by biopharmaceutical company Newron Pharmaceuticals, was being evaluated in the Phase III ENIGMA-TRS 2 study, targeting the modulation of excessive release of glutamate in patients suffering from… Read More

#News #Regulatory

Patient holding pill in hand
#Clinical trial #Combination therapy #Stroke

Combination therapy pill could reduce stroke risk by 40% 

A single pill low-dose combination therapy could reduce the risk of recurrent stroke by almost 40%, trial results show.  GMRx2, developed by biopharmaceutical company George Medicines, reduced recurrent stroke risk in patients with previous intracerebral haemorrhage (ICH) by 39% compared to placebo, according to results published in the New… Read More

#News

Weight loss concept
#Clinical trial #Obesity #Weight loss

Drug delivers 16% weight loss results in Phase III trial 

A new drug could lead to 16% weight loss in patients and improve metabolic health, Phase III results show.  Survodutide, a dual glucagon/GLP‑1 receptor agonist, has been developed by pharmaceutical company Boehringer Ingelheim for the treatment of adults living with obesity or overweight, without type 2 diabetes. … Read More

#News

#Clinical trial #Huntington's disease #Regulatory #uniQure

From the Editor: Terms and Conditions

The recent report that pharmaceutical company uniQure’s data from its Phase I/II studies provide insufficient evidence for the approval of its investigational gene therapy drug for Huntington’s disease (HD) are a major blow for patients.  Huntington’s disease is a rare genetic disorder that can affect around 5-10 people per 100,000, and which is… Read More

#Exclusive Content #Opinion

#Clinical trial #Freya Biosciences #Women's health

Freya Biosciences reports positive data on IVF therapeutic 

Immunology company Freya Biosciences has reported positive Phase I results for its treatment for IVF-related embryo implantation failure.  FB301, a defined multi-strain Lactobacillus consortium developed using Freya’s Dyscover platform, was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met.  The trial was a… Read More

#News

ulcerative colitis
#Biotech #Clinical trial #Ulcerative colitis (UC)

Spyre Therapeutics reports positive data for UC treatment 

Biotechnology company Spyre Therapeutics has reported positive results for its treatment for moderate-to-severely-active ulcerative colitis (UC).  SPY001, a potential best-in-class anti-α4β7, met its primary endpoint in a Phase II trial, with a significant reduction of 9.2 points from baseline at Week 12 in Robart’s Histopathology Index (RHI) score. Read More

#News